Last reviewed · How we verify

NCT03927430

Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen

Completed Last updated 1 May 2019
What this trial tests

trial testing pars plana vitrectomy with membrane peeling in Epiretinal Membrane in 40 participants. Completed in 1 March 2019.

Timeline
1 January 2019
Primary endpoint
1 March 2019
1 March 2019

Quick facts

Lead sponsorKlinikum Chemnitz gGmbH
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date1 January 2019
Primary completion1 March 2019
Estimated completion1 March 2019
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Klinikum Chemnitz gGmbH

Who can join

18 and older, any sex, with Epiretinal Membrane or Macular Holes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Surgical outcome of patients with macular drusen and co-existing abnormalities of the vitreoretinal interface, who routinely undergo pars plana vitrectomy with membrane peeling, is evaluated. Best corrected visual acuity as well as optical coherence tomography data are compared at baseline and last follow up. The rate of development of choroidal neovascularization postoperatively is noted.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. To Peel or Not to Peel: Pars Plana Vitrectomy with Macular Membrane Peel in Eyes with Abnormalities of Vitreomacular Interface and Coexisting Dry Age-Related Macular Degeneration.
    Furashova O, Engelmann K. · · 2020 · cited 5× · PMID 32103885 · DOI 10.2147/opth.s240480

Verify or expand the search:

Other recruiting trials for Epiretinal Membrane

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing